Realistically, what known event is going to cause this stock to re-rate? Based off the market reaction to the PTX100 results, the PTX200 readout will have little, if any, impact on the shareprice. The market knows about the 4 CRs in that study, so if there are no additional responses then nothing will happen here. The commencement of the CAR-T clinical trials won't have any impact since it will just be a phase 1 study. The only thing that could propel this is the FDA grant of registrational study for PTX100. Wouldn't expect to hear anything about this until closer to year-end. We will see 6-7c again pretty soon I imagine.
PTX Price at posting:
9.5¢ Sentiment: Buy Disclosure: Held
